Evidence map›Paper›PMID 26284929›Full record

ArticlePloS one2015

Discovery of Power-Law Growth in the Self-Renewal of Heterogeneous Glioma Stem Cell Populations.

Michiya Sugimori, Yumiko Hayakawa, Bruce M Boman, Jeremy Z Fields, Miharu Awaji, Hiroko Kozano, Ryoi Tamura, Seiji Yamamoto, Toru Ogata, Mitsuhiko Yamada and 3 more

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Michiya SugimoriDepartment of Integrative Neuroscience, University of Toyama, 2630 Sugitani, Toyama, Toyama 930-0194, Japan.
Yumiko HayakawaDepartment of Neurosurgery, University of Toyama, 2630 Sugitani, Toyama, Toyama 930-0194, Japan.
Bruce M BomanCenter for Translational Cancer Research, Departments of Biology and Mathematics, University of Delaware, Helen F Graham Cancer Center and Research Institute, Newark, DE 19711 United States of America.
Jeremy Z FieldsBiotechnical Research, CATX, Inc., Gladwyne, PA 19035 United States of America.
Miharu AwajiDepartment of Integrative Neuroscience, University of Toyama, 2630 Sugitani, Toyama, Toyama 930-0194, Japan.
Hiroko KozanoDepartment of Integrative Neuroscience, University of Toyama, 2630 Sugitani, Toyama, Toyama 930-0194, Japan.
Ryoi TamuraDepartment of Integrative Neuroscience, University of Toyama, 2630 Sugitani, Toyama, Toyama 930-0194, Japan.
Seiji YamamotoDepartment of Pathology, University of Toyama, 2630 Sugitani, Toyama, Toyama 930-0194, Japan.
Toru OgataThe Center of Sports Science and Health Promotion in the NRCD Hospital, National Rehabilitation Center for Persons with Disabilities, 4-1 Namiki, Tokorozawa, Saitama 359-8555, Japan.
Mitsuhiko YamadaDepartment of Neuropsycopharmacology, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi, Kodaira, Tokyo 187-8553, Japan.
Shunro EndoDepartment of Neurosurgery, University of Toyama, 2630 Sugitani, Toyama, Toyama 930-0194, Japan.
Masanori KurimotoDepartment of Neurosurgery, University of Toyama, 2630 Sugitani, Toyama, Toyama 930-0194, Japan.
Satoshi KurodaDepartment of Neurosurgery, University of Toyama, 2630 Sugitani, Toyama, Toyama 930-0194, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAccumulating evidence indicates that cancer stem cells (CSCs) drive tumorigenesis. This suggests that CSCs should make ideal therapeutic targets. However, because CSC populations in tumors appear heterogeneous, it remains unclear how CSCs might be effectively targeted. To investigate the mechanisms by which CSC populations maintain heterogeneity during self-renewal, we established a glioma sphere (GS) forming model, to generate a population in which glioma stem cells (GSCs) become enriched. We hypothesized, based on the clonal evolution concept, that with each passage in culture, heterogeneous clonal sublines of GSs are generated that progressively show increased proliferative ability. METHODOLOGY/PRINCIPAL

findingsTo test this hypothesis, we determined whether, with each passage, glioma neurosphere culture generated from four different glioma cell lines become progressively proliferative (i.e., enriched in large spheres). Rather than monitoring self-renewal, we measured heterogeneity based on neurosphere clone sizes (#cells/clone). Log-log plots of distributions of clone sizes yielded a good fit (r>0.90) to a straight line (log(% total clones) = k*log(#cells/clone)) indicating that the system follows a power-law (y = xk) with a specific degree exponent (k = -1.42). Repeated passaging of the total GS population showed that the same power-law was maintained over six passages (CV = -1.01 to -1.17). Surprisingly, passage of either isolated small or large subclones generated fully heterogeneous populations that retained the original power-law-dependent heterogeneity. The anti-GSC agent Temozolomide, which is well known as a standard therapy for glioblastoma multiforme (GBM), suppressed the self-renewal of clones, but it never disrupted the power-law behavior of a GS population. CONCLUSIONS/SIGNIFICANCE: Although the data above did not support the stated hypothesis, they did strongly suggest a novel mechanism that underlies CSC heterogeneity. They indicate that power-law growth governs the self-renewal of heterogeneous glioma stem cell populations. That the data always fit a power-law suggests that: (i) clone sizes follow continuous, non-random, and scale-free hierarchy; (ii) precise biologic rules that reflect self-organizing emergent behaviors govern the generation of neurospheres. That the power-law behavior and the original GS heterogeneity are maintained over multiple passages indicates that these rules are invariant. These self-organizing mechanisms very likely underlie tumor heterogeneity during tumor growth. Discovery of this power-law behavior provides a mechanism that could be targeted in the development of new, more effective, anti-cancer agents.

Indexed as

Cell Self RenewalCell Line, TumorCell ProliferationCell SizeClone CellsDacarbazineGliomaHumansModels, BiologicalMolecular Targeted TherapyNeoplastic Stem CellsTemozolomideDacarbazineTemozolomide

Identifiers

PMID26284929
PMCPMC4540573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.